Market Research Logo

Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026

Hypercalcemia Treatment Market: Global Industry Analysis & Opportunity Assessment, 2016-2026

Hypercalcemia is a condition caused by above normal levels of calcium in the body, with serum calcium level greater than 2.6 mmol/L. It is a life threatening metabolic disorder associated with neoplastic diseases and occurs in 10% to 20% of all adults suffering from cancer; particularly lung and breast cancer, and myeloma.

Early diagnosis of hypercalcemia by hydration and treatment with agents – to decrease serum calcium concentrations – also known as hypocalcemic drugs can produce symptomatic improvements within three to five days. The scope of hypercalcemia treatment market study is for Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics for treatment of malignancy-related hypercalcemia.

Market Dynamics

Primary factors fuelling demand for hypercalcemia treatment include increasing prevalence of hyperparathyroidism-related hypercalcemia, growing number of patients with cancers, higher incidence of multiple myeloma, availability of appropriate drug therapy alternatives over surgery, favourable reimbursement scenario and drug therapies to avoid kidney failure.

Market Segmentation by Product Type

Based on product type, the market has been segmented into Bisphosphonates (Clodronate, Etidronate, Ibandronate, Pamidronate and Zoledronic acid), Calcitonin, Glucocorticoids, Denosumab and Calcimimetics.

Market Segmentation by Distribution Channel

Revenue from the independent pharmacy and drug stores segment is expected to grow at a very fast pace, and contribute significantly towards distribution of hypercalcemia drugs during the forecast period. Hospitals distribution channel segment is projected to generate comparatively high revenue owing to novel and easy availability of hypercalcemia treatment drugs worldwide.

Market Value and Forecast

Global hypercalcemia treatment market revenue is projected to expand at a CAGR of 11.2% during forecast period 2016–2026, and a reach a value of US$ 25,230.2 Mn by the end of 2026.

Key Regions

The global hypercalcemia treatment market has been segmented into seven major regions: North America, Latin America, Western Europe, Eastern Europe, Asia Pacific excluding Japan (APEJ), Japan and Middle East & Africa (MEA). In terms of value, North America is estimated to be the dominant market in 2016 end, with revenue contribution expected to expand at a CAGR of 11.4% over the forecast period. Also, North America is estimated to witness comparatively faster growth in terms of revenue over the forecast period. Western Europe hypercalcemia treatment market is expected to register a CAGR of 11.3% in revenue terms over the forecast period. Bisphosphonates segment revenue in the North America hypercalcemia treatment market is expected to register a CAGR of 11.3% over the forecast period, with growth driven by increasing prevalence of cancer and myeloma among the populace in the region.


global hypercalcemia treatment market

Key Players

Some key players in the global hypercalcemia treatment market that have been identified in this report include Bayer Pharma AG, Sun Pharmaceutical Industries Ltd., Mylan N.V., Pfizer Inc., Amgen Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd. and Cipla Inc. The report also identifies company-specific strategies related to market consolidation initiatives and analysis of their specific strengths, weaknesses, opportunities and threats.


1. Executive Summary
2. Market Introduction
2.1. Market Definition
2.2. Market Taxonomy
3. Global Hypercalcemia Treatment Market Analysis Scenario
3.1. Market Size (US$ Mn) and Forecast
3.1.1. Market Size and Y-o-Y Growth
3.1.2. Absolute $ Opportunity
4. Market Dynamics
4.1. Macro-economic Factors
4.2. Drivers
4.2.1. Supply Side
4.2.2. Demand Side
4.3. Restraints
4.4. Opportunity
5. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Product Type
5.1. Introduction
5.2. Basis Point Share (BPS) Analysis By Product Type
5.3. Y-o-Y Growth Projections By Product Type
5.4. Market Value Forecast By Product Type , 2014–2026
5.4.1. Bisphosphonates
5.4.1.1. Clodronate
5.4.1.2. Etidronate
5.4.1.3. Ibandronate
5.4.1.4. Pamidronate
5.4.1.5. Zoledronic acid
5.4.2. Calcitonin
5.4.3. Glucocorticoids
5.4.4. Denosumab
5.4.5. Calcimimetics
5.5. Prominent Trends
5.6. Market Attractiveness By Product Type
6. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Distribution Channel
6.1. Introduction
6.2. Basis Point Share (BPS) Analysis By Distribution Channel
6.3. Y-o-Y Growth Projections By Distribution Channel
6.4. Market Value Forecast By Distribution Channel , 2014–2026
6.4.1. Hospitals
6.4.2. Clinics
6.4.3. Independent Pharmacy and Drug Stores
6.5. Prominent Trends
6.6. Market Attractiveness By Distribution Channel
7. Global Hypercalcemia Treatment Market Analysis and Forecasts, By Region
7.1. Basis Point Share (BPS) Analysis By Region
7.2. Y-o-Y Growth Projections By Region
7.3. Market Value Forecast By Region
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. APEJ
7.3.6. Japan
7.3.7. MEA
7.4. Market Attractiveness By Country/Region
8. North America Hypercalcemia Treatment Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis By Country
8.1.2. Y-o-Y Growth Projections By Country
8.2. Market Value Forecast By Product Type , 2014–2026
8.2.1. Bisphosphonates
8.2.1.1. Clodronate
8.2.1.2. Etidronate
8.2.1.3. Ibandronate
8.2.1.4. Pamidronate
8.2.1.5. Zoledronic acid
8.2.2. Calcitonin
8.2.3. Glucocorticoids
8.2.4. Denosumab
8.2.5. Calcimimetics
8.3. Market Value Forecast By Distribution Channel , 2014–2026
8.3.1. Hospitals
8.3.2. Clinics
8.3.3. Independent Pharmacy and Drug Stores
8.4. Market Value Forecast By Country , 2014–2026
8.4.1. U.S.
8.4.2. Canada
8.5. Market Attractiveness Analysis
8.5.1. By Product Type
8.5.2. By Distribution Channel
8.5.3. By Country
8.6. Prominent Trends
8.7. Drivers and Restraints: Impact Analysis
9. Latin America Hypercalcemia Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis By Country
9.1.2. Y-o-Y Growth Projections By Country
9.2. Market Value Forecast By Product Type , 2014–2026
9.2.1. Bisphosphonates
9.2.1.1. Clodronate
9.2.1.2. Etidronate
9.2.1.3. Ibandronate
9.2.1.4. Pamidronate
9.2.1.5. Zoledronic acid
9.2.2. Calcitonin
9.2.3. Glucocorticoids
9.2.4. Denosumab
9.2.5. Calcimimetics
9.3. Market Value Forecast By Distribution Channel , 2014–2026
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Independent Pharmacy and Drug Stores
9.4. Market Value Forecast By Country , 2014–2026
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Argentina
9.4.4. Rest Of Latin America
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
9.6. Prominent Trends
9.7. Drivers and Restraints: Impact Analysis
10. Western Europe Hypercalcemia Treatment Market Analysis and Forecast
10.1.Introduction
10.1.1. Basis Point Share (BPS) Analysis By Country
10.1.2. Y-o-Y Growth Projections By Country
10.2.Market Value Forecast By Product Type , 2014–2026
10.2.1. Bisphosphonates
10.2.1.1. Clodronate
10.2.1.2. Etidronate
10.2.1.3. Ibandronate
10.2.1.4. Pamidronate
10.2.1.5. Zoledronic acid
10.2.2. Calcitonin
10.2.3. Glucocorticoids
10.2.4. Denosumab
10.2.5. Calcimimetics
10.3.Market Value Forecast By Distribution Channel , 2014–2026
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Independent Pharmacy and Drug Stores
10.4.Market Value Forecast By Country , 2014–2026
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Nordic countries
10.4.7. Rest Of Western Europe
10.5.Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country
10.6. Prominent Trends
10.7. Drivers and Restraints: Impact Analysis
11. Eastern Europe Hypercalcemia Treatment Market Analysis and Forecast
11.1.Introduction
11.1.1. Basis Point Share (BPS) Analysis By Country
11.1.2. Y-o-Y Growth Projections By Country
11.2.Market Value Forecast By Product Type , 2014–2026
11.2.1. Bisphosphonates
11.2.1.1. Clodronate
11.2.1.2. Etidronate
11.2.1.3. Ibandronate
11.2.1.4. Pamidronate
11.2.1.5. Zoledronic acid
11.2.2. Calcitonin
11.2.3. Glucocorticoids
11.2.4. Denosumab
11.2.5. Calcimimetics
11.3.Market Value Forecast By Distribution Channel , 2014–2026
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Independent Pharmacy and Drug Stores
11.4.Market Value Forecast By Country , 2014–2026
11.4.1. Russia
11.4.2. Poland
11.4.3. Rest Of Eastern Europe
11.5.Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country
11.6. Prominent Trends
11.7. Drivers and Restraints: Impact Analysis
12. APEJ Hypercalcemia Treatment Market Analysis and Forecast
12.1.Introduction
12.1.1. Basis Point Share (BPS) Analysis By Country
12.1.2. Y-o-Y Growth Projections By Country
12.2.Market Value Forecast By Product Type , 2014–2026
12.2.1. Bisphosphonates
12.2.1.1. Clodronate
12.2.1.2. Etidronate
12.2.1.3. Ibandronate
12.2.1.4. Pamidronate
12.2.1.5. Zoledronic acid
12.2.2. Calcitonin
12.2.3. Glucocorticoids
12.2.4. Denosumab
12.2.5. Calcimimetics
12.3.Market Value Forecast By Distribution Channel , 2014–2026
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Independent Pharmacy and Drug Stores
12.4.Market Value Forecast By Country , 2014–2026
12.4.1. China
12.4.2. India
12.4.3. ASEAN
12.4.4. Australia & New Zealand
12.4.5. Rest Of APEJ
12.5.Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country
12.6. Prominent Trends
12.7. Drivers and Restraints: Impact Analysis
13. Japan Hypercalcemia Treatment Market Analysis and Forecast
13.1.Introduction
13.1.1. Basis Point Share (BPS) Analysis By Country
13.1.2. Y-o-Y Growth Projections By Country
13.2.Market Value Forecast By Product Type , 2014–2026
13.2.1. Bisphosphonates
13.2.1.1. Clodronate
13.2.1.2. Etidronate
13.2.1.3. Ibandronate
13.2.1.4. Pamidronate
13.2.1.5. Zoledronic acid
13.2.2. Calcitonin
13.2.3. Glucocorticoids
13.2.4. Denosumab
13.2.5. Calcimimetics
13.3.Market Value Forecast By Distribution Channel , 2014–2026
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Independent Pharmacy and Drug Stores
13.4.Market Attractiveness Analysis
13.4.1. By Product Type
13.4.2. By Distribution Channel
13.5. Prominent Trends
13.6. Drivers and Restraints: Impact Analysis
14. MEA Hypercalcemia Treatment Market Analysis and Forecast
14.1.Introduction
14.1.1. Basis Point Share (BPS) Analysis By Country
14.1.2. Y-o-Y Growth Projections By Country
14.2.Market Value Forecast By Product Type , 2014–2026
14.2.1. Bisphosphonates
14.2.1.1. Clodronate
14.2.1.2. Etidronate
14.2.1.3. Ibandronate
14.2.1.4. Pamidronate
14.2.1.5. Zoledronic acid
14.2.2. Calcitonin
14.2.3. Glucocorticoids
14.2.4. Denosumab
14.2.5. Calcimimetics
14.3.Market Value Forecast By Distribution Channel , 2014–2026
14.3.1. Hospitals
14.3.2. Clinics
14.3.3. Independent Pharmacy and Drug Stores
14.4.Market Value Forecast By Country , 2014–2026
14.4.1. GCC Countries
14.4.2. South Africa
14.4.3. North Africa
14.4.4. Rest Of MEA
14.5.Market Attractiveness Analysis
14.5.1. By Product Type
14.5.2. By Distribution Channel
14.5.3. By Country
14.6. Prominent Trends
14.7. Drivers and Restraints: Impact Analysis
15. Competition Landscape
15.1.Competition Dashboard
15.2.Market Share Analysis By Company (2015)
15.3.Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
15.3.1. Bayer Pharma AG
15.3.2. Sun Pharmaceutical Industries Ltd.
15.3.3. Mylan N.V.
15.3.4. Pfizer Inc.
15.3.5. Amgen Inc.
15.3.6. Novartis AG
15.3.7. Dr. Reddy’s Laboratories Ltd.
15.3.8. Cipla Inc.
16. Assumptions and Acronyms Used
17. Research Methodology

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report